Rodenhuis S, McGuire J J, Narayanan R, Bertino J R
Cancer Res. 1986 Dec;46(12 Pt 1):6513-9.
An assay system was developed for the detection and classification of methotrexate resistance in fresh human leukemic cells. Mechanisms of resistance to be identified were: overexpression of dihydrofolate reductase, decreased cellular uptake of methotrexate, decreased affinity of dihydrofolate reductase for methotrexate, decreased polyglutamylation of methotrexate, and low thymidylate synthase activity. The initial screening procedure utilizes 3H release after addition of [5-3H]-2'-deoxyuridine as a measure of intracellular activity of thymidylate synthase and of DNA synthesis; 3H release is assayed after 3-h incubations with methotrexate, trimetrexate, or gamma-fluoromethotrexate and after 4-h incubations with these agents followed by a 6-h incubation in drug free medium. The pattern of DNA synthesis inhibition and recovery under these two sets of conditions establishes the presence or absence of methotrexate resistance and allows a tentative classification of the resistance mechanism involved. In combination with determinations of dihydrofolate reductase activity, methotrexate titration studies, and the determination of intracellular drug accumulations in vitro, the system is readily able to classify CCRF-CEM human leukemia cell lines possessing well defined mechanisms of resistance. The findings in seven leukemia patients are also reported. Applying tentative reference values, four patients showed biochemical evidence of methotrexate resistance: two patients had only a transport defect, one patient had evidence of both a transport defect and low thymidylate synthase activity, and one patient appeared to have decreased methotrexate polyglutamylation. Application of the assay system in larger numbers of patients is feasible and is required to establish adequate reference values for the evaluation of biochemical-clinical correlates.
已开发出一种检测系统,用于检测和分类新鲜人白血病细胞中的甲氨蝶呤耐药性。待确定的耐药机制包括:二氢叶酸还原酶过表达、甲氨蝶呤细胞摄取减少、二氢叶酸还原酶对甲氨蝶呤的亲和力降低、甲氨蝶呤多聚谷氨酸化减少以及胸苷酸合成酶活性降低。初始筛选程序利用加入[5-³H]-2'-脱氧尿苷后³H的释放来衡量胸苷酸合成酶的细胞内活性和DNA合成;在与甲氨蝶呤、三甲曲沙或γ-氟甲氨蝶呤孵育3小时后以及与这些药物孵育4小时后再在无药培养基中孵育6小时后测定³H的释放。在这两组条件下DNA合成抑制和恢复的模式确定了甲氨蝶呤耐药性的存在与否,并允许对所涉及的耐药机制进行初步分类。结合二氢叶酸还原酶活性测定、甲氨蝶呤滴定研究以及体外细胞内药物积累的测定,该系统能够轻松地对具有明确耐药机制的CCRF-CEM人白血病细胞系进行分类。还报告了7例白血病患者的研究结果。应用初步参考值,4例患者显示出甲氨蝶呤耐药的生化证据:2例患者仅有转运缺陷,1例患者有转运缺陷和低胸苷酸合成酶活性的证据,1例患者似乎甲氨蝶呤多聚谷氨酸化减少。在更多患者中应用该检测系统是可行的,并且需要建立足够的参考值以评估生化与临床的相关性。